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N-linked glycoproteinL1)/CADM3/IGSF4B/TSLL1/SynCAM3, from now on referred to as NECL1, is a neural
tissue-speciﬁc immunoglobulin-like cell–cell adhesion molecule which has Ca2+-independent homo- or
heterophilic cell–cell adhesion activity and plays an important role in the formation of synapses, axon bundles
andmyelinated axons. Hereweﬁrst detected the expression of NECL1 in human fetal and adult brains, andmouse
brains at different developmental stages. The results indicated that two bands with molecular weights of about
62kDa and 48kDawere found inhuman fetal brain,while only one bandwith amolecularweight of about 48 kDa
was found inhumanadult brain; twobandswithmolecularweightsof about 62kDaand48kDawhoseexpression
level gradually increasedwere also found frommouse E16 to P14,while only one bandwith amolecularweight of
about 48 kDawas found from P14. Bioinformatics analysis showed there were two putativeN-glycosylation sites
within human NECL1 at positions N25LS and N290KS and within mouse Necl1 at positions N23LS and N288KS,
respectively. There was no O-glycosylation site in either human NECL1 or mouse Necl1. Based on the results
of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with
humanwild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is
an N-linked glycoprotein with a single glycosylation site at position N290KS. Cell aggregation assay further
showed there was an increased adhesion activity after the glycosylation site mutation of NECL1 molecule.
© 2008 Elsevier B.V. All rights reserved.In multicellular organisms, cells communicate with each other by
their adhesive interactions which are essential for different cellular1. Introduction
functions such as morphogenesis, proliferation, differentiation and
migration [1]. This adhesion is mediated by cell adhesion molecules
which have been classiﬁed into four types: immunoglobulin super-
family, selectin, integrin, and cadherin families. Nectins and Nectin-
like molecules all belong to the immunoglobulin superfamily of cell–
cell adhesion molecules and play roles in the above processes [2]. Up
to now there are four members in the Nectin family (Nectin-1, 2, 3, 4)
and ﬁvemembers in the Nectin-likemolecule family (NECL 1, 2, 3, 4, 5)
based on binding ability to Afadin [2,3]. Among them, almost each
member can recognize itself or others in homo- or heterophilicural cell adhesion molecule;
olecule 2; NECL5, Nectin-like
pAb, polyclonal antibody; PSA,
+86 10 65240529.
), gaojing_pumc@yahoo.com.cn,
l rights reserved.manners. For instance, Nectin-3 can interact with NECL1, NECL2,
NECL5, Nectin-1, Nectin-2 and Nectin-3 itself [4]. NECL1 is exclusively
and highly expressed in the nervous system and plays a role in the
formation of synapses, axon bundles, myelinated axons and cerebellar
morphogenesis [5–8]. It has been found that NECL1 can interact with
NECL1, NECL2, NECL4, Nectin-1 and Nectin-3 but not with NECL5 or
Nectin-2 [6,9–11]. The 1,197 bp length ORF of human NECL1 and
1,191 bp length ORF of mouse Necl1 produce the protein NECL1 with a
theoretical molecular weight of 44 kDa. However, it was recently
reported that in the rat brain, amajor band approximately 48 kDa and a
minor band approximately 62 kDa of Necl1 were detected [8,12]. This
may be due to its post-translational modiﬁcations. However, little is
known about post-translational modiﬁcations of NECL1 up to now.
NECL2, which has signiﬁcant homology with NECL1 in the overall
coding sequences [5], has been reported to be anN-linked glycoprotein
[13,14]. For this reasonwe speculate that the variousmolecular weight
forms of NECL1 could also be the result of glycosylation.We report that
two putative N-glycosylation sites were predicted within both human
NECL1 and mouse Necl1. The expression pattern of NECL1 in human
fetal and adult brain tissues and in mouse brain tissues of different
developmental stages were characterized and it is shown that human
NECL1 is an N-linked glycoprotein with one N-glycosylation site at
N290KS which could play a role in cell adhesion.
Fig. 1. Veriﬁcation of the speciﬁcity of anti-NECL1 antibody. (a) Homologyalignment of the
cytoplasmic regions of humanNECL1 andNECL2,which share two conservedmotifs: FERM
bindingmotif and PDZbindingmotif. (b)Antibodywasproducedandpuriﬁedasdescribed.
Antiserumbefore (indicated by − below) and after puriﬁcation (indicated by + below)were
used inWestern blotwith puriﬁedGST-NECL2C fusionprotein and cell extracts from293ET
transfected with pcDNA-NECL1 as antigens. A speciﬁc bandwas detected about 48 kDa by
antibody after GST-NECL2 afﬁnity puriﬁcation. CB: Coomassie Blue stain. (c) Human adult
brain tissue extract and cell extracts from COS7 and 293ET transfected with control vector
and pcDNA-NECL1 were loaded to SDS-PAGE and detected by anti-NECL1 antibody.
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2.1. Polyclonal antibody preparation
Rabbit polyclonal antibody against human NECL1 was prepared as described before
[8]. Brieﬂy, the cDNA fragment encoding 47 amino acids of the cytoplasmic region of
human NECL1 was cloned into pET-30a-DHFR vector. The fusion protein was expressed
in BL21(DE3) bacteria and puriﬁed using a nickel column. New Zealand white rabbits
were immunized with the fusion protein to produce the antibody. Additionally, the
antiserum was applied to GST-NECL2C immobilized column for absorption of non-
speciﬁc antibodies. Montage Antibody Puriﬁcation Kit (Millipore) was further used to
purify the pure IgG and the speciﬁcity of the antibodies has been detected.
2.2. Tissue and cell lysates preparation and Western blot analysis
Human fetal brain tissue was kindly provided by Beijing Jishuitan Hospital and
human adult brain tissues were provided by Beijing Tiantan Hospital. Human fetal and
adult brain tissues, and different developmental stage mouse brain tissues were
homogenized in lysis buffer (50mMTris–HCl, pH 7.5,150mMNaCl,1 mMMgCl2,10mM
NaF, 1 mM NaVO3, 10% glycerol, 1% NP-40, 2 μg/ml aprotinin, 2 μg/ml leupeptin, 2 μg/ml
pepstatin and 2 μg/ml PMSF) on ice followed by shaking at 4 °C for 30 min. The lysates
were centrifuged at 12,000 rpm for 20 min at 4 °C, then supernatant was collected. To
prepare thewhole cell extracts, cell pellets were suspended in the above lysis buffer and
processed as the tissue lysates preparation. Protein concentration was determined
using the Bradford method, lysates were aliquoted and stored at −80 °C until use. The
Western blot analysis was performed as described [15] with rabbit pAb against NECL1 at
a dilution of 1:200 and mouse anti-V5 mAb (Invitrogen) at a dilution of 1:3000.
2.3. Bioinformatics analysis
Bioinformatics prediction of N- and O-glycosylation sites on human NECL1 and
mouse Necl1 were performed with the following database:
http://www.cbs.dtu.dk/services/NetOGlyc;
http://www.cbs.dtu.dk/services/NetNGlyc.
2.4. Lysates treated with N-Glycosidase F
Lysates were treated with N-Glycosidase F (Roche, Cat.No.1365185) according to the
manufacturer's instructions followed by Western blot with anti-NECL1 pAb (dilution:
1:200) or anti-V5 mAb (Invitrogen, dilution: 1:3000).
2.5. Plasmid construction
NECL1 ORF was ampliﬁed from the human fetal brain cDNA library with primers
(see Table 1) and cloned into pcDNA3.1(+), pcDNA3.1/V5-HisA vectors (Invitrogen) to
generate pcDNA-NECL1 and pcDNA3.1/V5-NECL1 (named as NECL1-WT), respectively.
For the mutant constructs of pcDNA3.1/V5-NECL1-N25A, pcDNA3.1/V5-NECL1-N290A
and pcDNA3.1/V5-NECL1-N25A+N290A, respectively, overlap PCR (to mutate N290 site)
and QuickChange Kit (Stratagene, to mutate N25 site) were employed (see Table 1).
2.6. Cell culture, transfection and establishment of stable cell line
Humanembryonic kidney 293ETcell line (kindly providedbyDr. Chengyu Jiang, Peking
Union Medical College) was maintained in Iscove's Modiﬁed Dulbecco's Medium (IMDM,
Gibco), COS7 cell line and L cell line (purchased from ATCC)were maintained in Dulbecco's
ModiﬁedEagle'sMedium(DMEM,Gibco)with10%heat-inactivatedFBS,100U/mlpenicillin
and 100 μg/ml streptomycin under a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C.
To establish L cells stably expressing NECL1 and mutant forms, cells were transfected
with NECL1-WT or NECL1-N290A using VigoFect (Vigorous,China) according to the
manufacturer's instructions. A control set of cells was transfected with empty vector
pcDNA3.1/V5-HisA. 24–48 h after transfection, the medium was changed with fresh
medium containing 500 μg/ml G418(Gibco, USA) to select stable colonies. After 2–3weeks
of selection, the stable colonies were maintained in the presence of 300 μg/ml G418.Table 1
Primers and their sequences used in plasmid constructions
Applications of primers Sequences
Amplify NECL1 ORF CCCAAGCTTATTATGGGGGCCCCAGCCG
CCGCTCGAGGATGAAATATTCCTTCTTGTCGTCCC
Mutate 25 site CGGGGCCGCCCTCTCCCAGGACG
CGTCCTGGGAGAGGGCGGCCCCG
Mutate 290 site CTGTCACTCTTGGCGAGGAAAGG
CCTTTCCTCGCCAAGAGTGACAG
The bold and italic letters represent the recognition sites of restriction enzymes HindIII
and XhoI respectively; letters underlined represent the sequence after mutation.2.7. Immunocytochemistry
Immunocytochemistry was performed as described [8]. Brieﬂy, cells were washed
with PBS twice andﬁxedwith 4% paraformaldehyde for 10min at RT, thenpermeabilized
with 0.5% TritonX-100 for 10min at RTand blockedwith 3% bovine serum albumin (BSA)
for 30min at 37 °C. The cellswere immunostained usingmouse anti-V5mAb (Invitrogen,
dilution: 1:200) and then followed by a FITC conjugated goat anti-mouse antibody. After
overlaying coverslips, the slides were imaged using a Leica confocal microscope.
2.8. Cell aggregation assay
Cell aggregation assay was performed as described [4]. Brieﬂy, cells werewashedwith
PBS, incubatedwith0.2% trypsin and1mMEDTAat37 °C for3min, anddispersedbygentle
pipetting. The cells were then suspended in Hanks' balanced salt solution (about 1×106
cells/ml), placed in 12-well plates precoatedwith bovine serum albumin, and rotated on a
gyratory shaker at 37 °C for about 15min. Aggregationwas stoppedwith the addition of 2%
glutaraldehyde. The extent of aggregation of cells was photographed using a microscope
with the magniﬁcation 100×. The volume of aggregates (cm3) was calculated using the
simpliﬁed formula for a rotational ellipsoid: a×b2×π/6 where a is the longest diameter of
an aggregate and b is the shortest diameter of the aggregate [22,23]. The volume of the
aggregate is the mean volume of at least six aggregates at 100× magniﬁcation.
3. Results
3.1. Veriﬁcation of the speciﬁcity of anti-NECL1 polyclonal antibody
DNAMAN software was used to compare the cytoplasmic regions
of human NECL1 and NECL2 (Fig. 1a). The identity of them was up to
75%, and two conserved motifs were concluded in their cytoplasmic
regions: FERM binding motif and PDZ binding motif. In order to prove
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Antiserum before and after puriﬁcation were used in Western blot
with puriﬁed GST-NECL2C fusion protein and cell extracts from 293ET
transfected with pcDNA-NECL1 as antigens. We can see that after
puriﬁcation, the anti-NECL1 antibody only recognized the NECL1
protein and a speciﬁc band was detected about 48 kDa. The Western
blot result of Fig. 1c indicated that the molecular weight of
endogenous NECL1 in human adult brain tissue and exogenous
NECL1 overexpressed in COS7 and 293ET cells were identical.
3.2. Determination of the molecular weight of NECL1 in human fetal
brain and adult brain tissues and in mouse brain tissues at different
developmental stages
Western blot was employed to detect the expression of NECL1
protein in human fetal and adult brain tissues (Fig. 2a) and in mouse
brain tissues at different developmental stages (Fig. 2b) using spe-
ciﬁc anti-NECL1 antibody. One major band approximately 48 kDa
was detected in both human fetal and adult brain tissues, while a
minor band about 62 kDa was detected only in human fetal but not
in adult brain tissues. Comparatively, a major band approximately
48 kDa was detected from mouse E16 up to P42 with gradually
increased expression level, while a faint band about 62 kDa was
detected during mouse E16 to P14 with also roughly increased
expression level, peaked at P14 and disappeared after P14. Both
bands (48 kDa, 62 kDa) were larger than the theoretical molec-
ular weight (44 kDa) possibly due to the post-translational modi-
ﬁcation(s), most likely glycosylation.
3.3. Two potential N-glycosylation sites are predicted in both human
NECL1 protein and mouse Necl1 protein
Bioinformatics prediction as described in Material and methods
showed that there are two potential N-glycosylation sites in the
extracellular region at positions N25LS and N290KS of human NECL1
and at the positions N23LS andN288KS ofmouseNecl1. No putativeO-
glycosylation site is predicted within NECL1 in either species. Because
the identity of NECL1 between human and mouse is up to 94.9%, andFig. 2. The expression pattern of NECL1 in one human fetal brain tissue, three adult
brain tissues and in mouse brain tissues at different developmental stages.Western blot
analysis with anti-NECL1 pAb in 10% SDS-PAGE (50 μg per lane) shows that there are
two bands with molecular weights of about 62 kDa and 48 kDa in human fetal brain
tissue, while only one band with a molecular weight of about 48 kDa is observed in
human adult brain tissues; a major band approximately 48 kDa was detected from
mouse E16 with gradually increased expression level, while a faint band about 62 kDa
was detected during mouse E16 to P14 with also increased expression level peaked at
P14 and disappeared after P14. The result of β-actin is included in the lower panel.the amino acid sequences of the cytoplasmic region of human and
mouse NECL1 are identical, their potential N-glycosylation sites
coincide perfectly (Fig. 3a). The prediction results and the structural
schematic diagram of human NECL1 are presented in Fig. 3b, c and d.
3.4. NECL1 is indeed N-glycosylated but with only one N-glycosylation
site
To address whether NECL1 is an N-linked glycoprotein, protein
extracts from human fetal brain andmouse P14 brainwere treatedwith
N-Glycosidase F and detected with anti-NECL1 antibody. The results in
Fig. 4a and b showed both two bands (48 kDa, 62 kDa) shifted to about
44 kDa which is perfectly matched with the theoretical molecular
weight of NECL1 after treated with N-Glycosidase F. Since both two
bands (48kDa, 62 kDa) disappeared afterN-Glycosidase F treatment and
appeared as only one band of about 44 kDa, we claimed that both two
bands (48 kDa, 62 kDa) are glycosylated by two possibilities, one is the
glycosylation thatoccurs at two sites and theotherone is glycosylation at
only one site in varying degrees. It could be interesting to determine if
these two predicted glycosylation sites are all responsible for the
glycosylation of NECL1 or not. Since the identity of NECL1 between
human andmouse is up to 94.9%, humanwild-type NECL1 and N25A or/
and N290A mutant NECL1 with V5 tag were overexpressed in 293ET
cells. First we veriﬁed the distribution of wild-type NECL1 and its
mutants by immunocytochemistry with anti-V5 antibody. As shown in
Fig. 5c, themembrane localization of all of theNECL1proteins (wild-type
and mutants) meant that the glycosylation sites didn't affect the
trafﬁcking of NECL1, aswell as the folding of the protein. Next treatment
of the lysates withN-Glycosidase F followed byWestern blot using anti-
V5 antibody (Fig. 5d) showed that overexpression of wild-type NECL1
was partially glycosylated (molecular weight, about 52 kDa) but after
treatmentwithN-Glycosidase F, the band shifted to 48 kDawhich equals
to the theoretical molecular weight (44 kDa) of NECL1 plus approxi-
mately 4 kDa added by V5 tag. The N25A mutant showed the same
molecular weight pattern with wild-type. However, for the N290A or
N25A+N290Amutant, therewas only one bandwith amolecularweight
of 48 kDa. These results implied that it is Asn290 but not Asn25
responsible for the glycosylation of NECL1.
3.5. N-glycosylation of NECL1 affects cell–cell adhesion activity
It has been reported that the glycosylation of many adhesion
molecules could affect the adhesion activity, such as NCAM [16]. So
hereinweaskedwhether theglycosylationofNECL1alsoplays some roles
in adhesion activity. Empty vector, NECL1-WT, NECL1-N25A and NECL1-
N290A were stably overexpressed in L cells. First we examined the
expression anddistribution of theseNECL1s on L cells. As shown in Fig. 6a
andb, thewild-typeandN25AmutantNECL1swereglycosylated in Lcells
whileN290AmutantNECL1wasunglycosylatedbasedon thecomparison
with Fig. 5d. Also, all NECL1 proteins were located on the membrane of L
cells as those in 293ETcells. Cell aggregation could be obviously observed
within theNECL1-WT,NECL1-N25AandNECL1-N290Astably transfected
L cells compared to the empty vector transfected L cells (Fig. 6c).
Moreover, the cell aggregates caused by aggregations within NECL1-
N290A stably transfected L cells were signiﬁcantly greater than those
foundwithNECL1-WTandNECL1-N25Astably transfected Lcells. The cell
aggregates observed in NECL1-N25A stably transfected L cells were not
signiﬁcantly different from those within NECL1-WT stably transfected L
cells (Fig. 6d). This result suggested the possibility that glycosylation of
NECL1 can inﬂuence adhesion activity to a certain extent.
4. Discussion
In this study, we ﬁrst reported human NECL1 is a glycoproteinwith
one N-glycosylation site at position N290. The two bands of NECL1
with molecular weights of about 48 kDa and 62 kDa observed in
Fig. 3. Amino acid sequence alignment between human and mouse NECL1 (a) and bioinformatics prediction of potential N-glycosylation (b) and O-glycosylation (c) sites. (a) The
identity of NECL1 between human and mouse is up to 94.9%, and the cytoplasmic region between them is identical. NLS and NKS which is marked with asterisks are putative N-
glycosylation sites both in human NECL1 and mouse Necl1. The transmembrane region is marked with a black box. (b and c) The abscissa represents the sequence of human NECL1
amino acids, and the longitudinal axis represents the actual predictive value with 0.5 as the threshold and 1 as the optimum prediction. (d) The schematic diagram of human NECL1
structure. S–S indicates a disulﬁde bond in the immunoglobulin-like domain; SP, EX, TM and CT indicate the signal peptide, extracellular domain, transmembrane, and cytoplasmic
domain, respectively. N25LS and N290KS represented by two black circles indicate putative N-glycosylation sites where 25 and 290 represent the position of Asparagine (N).
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different contents of glycosylation. The glycosylation sitewas detected
and further conﬁrmed by overexpression of NECL1 and its mutant
forms in 293ET cell line, which indicated that Asn290 residue is
essential for NECL1 glycosylation, and the glycosylation could
inﬂuence the adhesion activity in a certain extent.Kakunaga et al. reported that, in rat for NECL1, there is a band with
amolecular weight of about 62 kDa observed during postnatal days 6–
14, after which time it disappeared [6]. Interestingly, we observed that
one major band of approximately 48 kDa was detected in both human
fetal and adult brain tissues, while a minor band of about 62 kDa was
only detected in human fetal but not in adult brain tissues. In mouse,
Fig. 4.Western blot analysis of NECL1 in human fetal brain tissue (a) and mouse P14 brain tissue (b) treated with or without N-Glycosidase F. The samples treated with or without N-
Glycosidase F were subjected to 10% SDS-PAGE (50 μg per lane) and detected by anti-NECL1 pAb. The two bands (48 kDa, 62 kDa) in human fetal brain tissue and mouse P14 brain
tissue all became smaller to about 44 kDa after treatment with N-Glycosidase F.
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gradually increased expression level; another faint band of about 62 kDa
was detected during mouse E16 to P14. Its expression level roughly
increased fromE16 to P14with an expressionpeak at P14, then the band
disappeared. Two bands (48 kDa, 62 kDa) both shifted to 44 kDa after
treatmentwithN-Glycosidase F, sowe conclude that these two bands of
62 kDa and 48 kDa are glycosylated. Since there are two predicted
putative glycosylation sites withinmouse and humanNECL1, it could beFig. 5. Identiﬁcation of N-glycosylation site of human NECL1 in vitro. (a and b) Sequencing re
and after mutation. AAC mutated to GCC as shown above. (c) Results of immunocytochemist
constructs of NECL1. Both wild-type NECL1 and mutated NECL1 are located on the membra
different mutation constructs of human NECL1. The lysates were treated with or without N-argued that these twomolecular weights of NECL1 have been caused by
glycosylation at these two sites. Overexpression of NECL1 and its
glycosylation site mutants indicated that NECL1 only has one glycosyla-
tion site at Asn290. Thus, two bands could be further explained by
glycosylation at Asn290 in varying degrees.
It must be mentioned that the molecular weight pattern among
the three different species (human, mouse and rat) is similar during
development, although it is difﬁcult to get the human brain tissuessults of two putative N-glycosylation sites (N25 and N290) within human NECL1 before
ry with anti-V5 mAb in 293ET cell line transfected with wild-type or different mutation
ne. Scale, 20 μm. (d) Western blot analysis of 293ET cells transfected with wild-type or
Glycosidase F and then subjected to 10% SDS-PAGE (50 μg per lane). WB: anti-V5 mAb.
Fig. 6. Cell–cell adhesion activity of wild-type and mutant human NECL1. (a) Cell lysates from L cells were subjected to 10% SDS-PAGE (50 μg per lane), followed by Western blot
analysis using anti-V5 mAb. (b) Results of immunocytochemistry with anti-V5 mAb in L cells. Both wild-type NECL1 and its mutants are located on the membrane. Scale, 20 μm.
(c) Cell aggregation activity of NECL1 when a single-cell suspensionwas rotated for 15min. (c1) Wild-type L cells; (c2) NECL1-WT L cells; (c3) NECL1-N25A L cells; (c4) NECL1-N290A
L cells. The results shown are representative of three independent experiments. Scale, magniﬁcation 100×. (d) Quantitative results of aggregates' size in L cells. ⁎⁎Pb0.05.
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glycoproteins contain several forms with different contents of
glycosylation, and one of the well-studied is NCAM (neural cell
adhesion molecule). Seki et al. showed that NCAM is highly
polysialylated (NCAM-H) during the late embryonic and early
postnatal stages, but less polysialylated (NCAM-L) during the early
embryonic and adult stages [17]. So the results from Kakunaga's data
as well as ours suggest that glycosylation of NECL1 maybe also play
some role in the development of brain among different species.
Until now, the different glycosylated forms of NCAM have been
shown to be dominantly regulated by two polysialyltransferases, PST
(ST8SiaIV) and STX (ST8Sia II). PST and STX both would form polysialic
acid in NCAM, however, polysialic acid synthesized by PST is larger
(∼60 sialic acids) than that synthesized by STX (∼40 sialic acids)
[18,19]. It was also reported PST cooperating with STX could add a
longer polysialic acid to NCAM than PST alone. As the molecular
weight of a sialic acid is about 310 Da, the N-glycans added by PST and
STX should be ∼18 kDa and ∼12 kDa, individually. Considering thatthere are 6 N-glycosylation sites lying in NCAM and 3 different
isoforms of NCAM, theWestern blot result of NCAM always indicates a
smear band around 200 kDa [19]. Although the precise mechanism of
how NECL1 is glycosylated at the single site during brain development
and the type of glycan needs to be further investigated, the model
of NCAM polysialylation should give us some useful clues for the
glycosylation of NECL1.
The result of cell aggregation assay showed that there is an
increased adhesion activity after the glycosylation site was mutated. It
has been proved that the steric properties of polysialic acid (PSA) can
hinder the apposition of cell membranes regulated both by NCAM and
by other molecules [16]. Sialic acid is a negative charge enriched and
hydrophilic molecule, which can form a big hydrate radius [20]. The
existing of PSA in NCAMwould increase the distance between NCAMs
and reduce the binding force between them, which caused the
distance between other adhesion molecules being increased to inhibit
their binding. Therefore the adhesion between cells would be
disrupted by NCAM-H. This change could be necessary for neurite
1435J. Gao et al. / Biochimica et Biophysica Acta 1778 (2008) 1429–1435outgrowth and axon expansion during the late embryonic and early
postnatal stages. The homo-interaction between NECL1 may be also
regulated by glycosylation similar to the NCAM mechanism. However,
how the glycosylation affects the adhesion activity of human NECL1
remains to be further addressed. It is also amysterywhy overexpression
of NECL1 in the cells (293ET, L cells) leads to low glycosylation.
It has also been shown that NECL1 is a Ca2+-independent homo- or
heterophilic cell–cell adhesion molecule which can interact with
NECL1, NECL2, NECL4, Nectin-1and Nectin-3 by forming cis-dimers
ﬁrst, followed by forming trans-dimers but not with NECL5 and
Nectin-2 [6,9]. The crystal structure of the ﬁrst Ig domain of NECL1
indicates that Phe82 is a key residue for the trans-adhesion activity of
NECL1 [21]. It will be also interesting to ask whether the glycosylation
of NECL1 involves in the cis-adhesion activity localized at non-
junctional contact sites of presynaptic nerve terminals, axons and glia
cell [6] during brain development.
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